Paion
Paion's phase III stroke study on target to be fully enrolled by year end
Published in Medicine and Law Weekly, August 25th, 2006
Additionally, two of the study's three planned interim safety analysis have already been conducted, the second recently. No safety concerns were raised by the data monitoring committee and continuation of the study was approved. Specifically, the rate of symptomatic bleedings, which is a major concern of treating physicians, has been below predefined levels.
The study explores the efficacy of Paion's drug candidate Desmoteplase in acute ischaemic stroke and was started in 2005 Forest Laboratories Inc. It is slated...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
More Articles from Medicine and Law Weekly
- Alnylam Pharmaceuticals
Alnylam reports loss of $0.31 per share - Aomori Municipal Hospital, Aomori, Japan
Coronary artery bypass grafting using an abdominal artery as an inflow is described - BioMag
BioMag files application for a multi-assay diagnostic system designed for blood banks - Biomedical Primate Research Center, Rijswijk, Netherlands
Relative neutralization sensitivity/resistance is HIV-1 type B isolate reproducible property - Biosite
Biosite notes 45% increase in sales of cardiovascular products - Business & Finance
Chemed reports second-quarter 2006 results - More from this issue of Medicine and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
